Etirinotecan pegol
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anaplastic Astrocytomas
Conditions
Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM)
Trial Timeline
Jul 1, 2012 → Feb 1, 2015
NCT ID
NCT01663012About Etirinotecan pegol
Etirinotecan pegol is a phase 2 stage product being developed by Nektar Therapeutics for Anaplastic Astrocytomas. The current trial status is completed. This product is registered under clinical trial identifier NCT01663012. Target conditions include Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM).
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01663012 | Phase 2 | Completed |
Competing Products
20 competing products in Anaplastic Astrocytomas
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CS-7017 + Paclitaxel | Daiichi Sankyo | Phase 1/2 | 41 |
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | 52 |
| Lenvatinib 24 mg | Eisai | Phase 2 | 52 |
| Lenvatinib + Nivolumab | Ono Pharmaceutical | Phase 2 | 52 |
| durvalumab + tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| LDK378 + AUY922 | Novartis | Phase 1 | 33 |
| ceritinib | Novartis | Pre-clinical | 23 |
| LDK378 | Novartis | Phase 1 | 33 |
| Ceritinib | Novartis | Phase 2 | 52 |
| Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim | Novartis | Phase 1 | 33 |
| dabrafenib/trametinib | Novartis | Phase 2 | 52 |
| Trametinib + Paclitaxel | Novartis | Phase 1 | 33 |
| Alectinib + Crizotinib | Roche | Phase 3 | 77 |
| Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Crizotinib (PF-02341066) | Pfizer | Phase 2 | 51 |
| Lorlatinib | Pfizer | Phase 2 | 51 |
| Crizotinib | Pfizer | Phase 1/2 | 40 |
| Cemiplimab + XL092 | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Bevacizumab | Novocure | Phase 2 | 47 |
Other Products from Nektar Therapeutics
NKTR-102 + Eribulin + Ixabepilone + Vinorelbine + Gemcitabine + Paclitaxel + Docetaxel + Nab-paclitaxelPhase 3
72
NKTR-181 BID tablets + Placebo to match NKTR-181 BID tabletsPhase 3
72
NKTR-102 + Treatment of Physician's Choice (TPC)Phase 3
72
NKTR-181 BID tabletsPhase 3
72
NKTR-255 at 1.5 µg/kg + NKTR-255 at 3.0 μg/kg + NKTR-255 at 3.0/6.0 μg/kgPhase 2/3
60